The new software, SIFT 4G, accelerates genome analysis by preparing predictions at a much higher speed, reducing processing time from 25 days to just three days on a single GPU. This enables researchers to analyze genomes in five minutes, advancing science and developing technology that can benefit human health.
Researchers from IMCB identified 303 genes linked to proviral silencing, revealing coordinated mechanisms involving multiple cellular pathways. The study found that Chaf1a and Sumo2 are the key factors controlling this process, with potential implications for stem cell therapy and disease diagnosis.
Scientists developed a predictive tool to identify sequences that can cause mutations, DNA breaks, and diseases in genomes. The tool found 75% of human genes contain R-loop Forming Sequences, with an accuracy of 80-90% in predicting their locations.
Researchers at A*STAR's Genome Institute of Singapore have developed an expert system called OncoIMPACT that combines cancer omics data with machine learning models to predict treatment targets. The system has been applied to over a thousand cancers, including melanomas and ovarian cancers, and shows promise for personalized medicine.
A study reveals that infants with a mature gut bacteria profile at an early age tend to have normal levels of body fat by 18 months, while those with less mature profiles are more likely to have lower body fat. The research found that gestational duration and delivery method influenced the rate of bacterial colonization in the infant gut.
The Institute of Bioengineering and Nanotechnology has developed a paper-based disposable device to detect dengue-specific antibodies from saliva, enabling early diagnosis and treatment. The device can differentiate between primary and secondary dengue infections, reducing the risk of severe complications.
A*STAR scientists identified a genetic pathway responsible for the size of the human brain, which accounts for superior cognitive abilities. The KATNB1 gene is essential for central nervous system development in humans and other animals.
Scientists have discovered that Metformin can boost the efficacy of TB medication and stop Mtb replication without promoting drug resistance. This discovery could lead to a new and affordable treatment strategy for tuberculosis, potentially shortening clinical trials.
Researchers at A*STAR's Genome Institute of Singapore identified a biomarker called RASAL2 strongly associated with triple negative breast cancer, a highly aggressive form of the disease. High expression levels of RASAL2 in TNBC tumors correlate with lower survival rates and increased metastasis.
Researchers have established a crucial relationship between Natural Killer T (NKT) cells and B cells in the body's natural defense mechanisms. The study found that altered lipid compositions on autoimmune B cells lead to over-activation of NKT cells, causing their depletion. Removing a specific lipid-presenting molecule from B cells re...
Scientists have discovered genes in zebrafish that may be synonymous with human airway genes, which could lead to new treatments for Primary Ciliary Dyskinesia (PCD) and other respiratory diseases. The study identified hundreds of novel genes associated with cilia formation, shedding light on the causes of defective motile cilia.
The study provides a comprehensive understanding of the liver fluke's molecular pathways, which may lead to the development of powerful diagnostic tools and effective treatments for parasite-specific diseases. The findings offer new insights into the life cycle of the parasitic fluke in the human bile duct.
A Singaporean birth cohort study found that six-month-old bilingual infants outperformed monolingual peers in recognizing familiar images and paying attention to novelty. This suggests a generalized cognitive advantage that emerges early in bilingual children, which may have implications for their future pre-school developmental outcomes.
Scientists from A*STAR's Bioprocessing Technology Institute uncover crucial role of DOK3 and SHP1 in plasma cell development and production. This discovery advances understanding of plasma cells and antibody response, potentially leading to improved treatment for patients with autoimmune diseases like lupus and multiple myeloma.
Scientists have identified a novel gene that predicts both breast cancer relapse and response to chemotherapy, enabling doctors to classify patients for more effective treatment. The discovery could help reduce metastasis and increase the effectiveness of chemotherapy.
Researchers at A*STAR's Institute of Medical Biology have identified a biomarker, Lgr5, to detect ovarian cancer earlier. Bioinformatics analysis has also revealed genes whose mutation status can be used for prognosis and development of personalized treatment.
Researchers have developed a first-of-its-kind molecular test kit that can predict treatment and survival outcomes in kidney cancer patients based on their tumor profile. The assay was able to distinguish patients into groups with different survival and treatment outcomes, allowing for more educated choices in treatment options.
A*STAR's Bioprocessing Technology Institute has partnered with Roche to develop new cancer treatments using novel antibodies that can directly target and destroy cancer cells. The partnership aims to improve cancer detection and treatment, offering a potential breakthrough in cancer therapy.
A*STAR scientists discovered that obese individuals lack a crucial protein essential for regulating blood glucose levels, increasing their risk of developing diabetes. The protein, NUCKS, is the first molecular link found between obesity and diabetes, opening up new areas of research for potential treatments.
Researchers identify a novel mode of cancer cell recognition by the immune system, opening up new possibilities for leukemia immunotherapy. A specific group of immune cells, called mLPA-specific T-cells, recognize and destroy leukemia cells triggered by the newly identified lipids.
A recent study discovered that both genetic factors and prenatal environments play a crucial role in shaping a baby's development. The research, led by A*STAR's Singapore Institute for Clinical Sciences, found that genetic differences alone account for only 25% of epigenetic variation, while environmental factors contribute up to 75%.
Scientists at A*STAR's IMCB develop a method to generate human induced pluripotent stem cells from a single drop of finger-pricked blood. This technique enables donors to collect their own blood samples, potentially boosting recruitment and diversities of donors for large-scale hiPSC banks.
Researchers identified SNX27's precise role in the pathway leading to memory and learning impairment, particularly in Down's syndrome. The study could lead to strategies to improve memory and learning abilities in those with the condition.